CTI/Baxalta Withdraw Pacritinib NDA Following More Deaths
This article was originally published in Scrip
Things have gone from bad to worse for CTI BioPharma Corp. this week. Shares lost 60% of their value to close at $0.44 on Feb. 8 following news the US FDA had placed a partial clinical hold on myelofibrosis treatment candidate pacritinib. And now, the company has received further communication from the FDA that the IND for pacritinib has been placed on full clinical hold.
Register for our free email digests: